Drug Use Investigation of Regorafenib/STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Registrational
- Sponsors Bayer
- 23 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 23 Nov 2018 Planned primary completion date changed from 30 Jun 2021 to 30 Nov 2020.
- 28 Apr 2018 Planned End Date changed from 25 Jun 2021 to 30 Jun 2021.